Is "Maybe next time" code for "Maybe never"? ?????♀?

Is "Maybe next time" code for "Maybe never"? ????♀?

Greetings!

It was my dad who started preparing me for the learning mindset I’d need to adopt as a scientist. Whenever I’d moan about having to study while other kids were playing outside, without fail, he’d say:

“This is how life is, you never stop having to learn new things—I’m in the same boat as you!”?

I always found his response exasperating, though of course, he was right.

Being a scientist means nothing is ever set in stone. You don’t just have to keep up with all the new findings that come out on a daily basis. You’ll likely also have to spend time un-learning methods that you picked up over your early career, where you may have been taught a particular way of doing things that’s “okay,” but isn’t optimal.

Except that finding the space to learn?when you’re stressed out by projects with tight deadlines isn’t easy. On top of the time and energy you invest in learning a new method, putting it into practice for the first time can take longer than expected.?

It’s no secret that as a company, we’re big advocates for adopting Design of Experiments (DOE). It’s a methodology that, overall, takes less effort, and gives you better quality data and deeper insights—all by looking at how multiple variables (known as factors) interact with each other, instead of looking at one factor at a time (OFAT). Taking the time to learn it sounds like a no-brainer.?

But then you think, “Hey, I really have to show some results at that next team meeting. I think I'm going to stick with OFAT just this once, and maybe next time I'll try DOE.” Only next time the pressure's still on and it feels easier not to, and the same thing happens again and again. Yet by sticking with OFAT, you’ll spend more time in the lab, and you’ll get less valuable information out.

So, how do you break that cycle?

To me, it's about alleviating some of that pressure. You need to be given that time to learn. Though many organizations realize the benefits of upskilling their employees, there's still some way to go.

In the meantime, every minute you can carve out for learning is still better than none at all.?

'Til the next one,

—Luci, Senior Research Scientist, Synthace


?? Speaking of minutes, have you got 6?

That's all our resident DOE experts Michael (aka Sid) Sadowski and James (JAJA) Arpino need to teach you the DOE fundamentals.

Start learning DOE in just 6 minutes a day with their free 8-day email course. Did we mention it's live???

Sign me up?

????? "We're lending you our experience"

How Synthace's Global Manager and DOE evangelist Ross Kent describes Sid and JAJA's new DOE course.

The most difficult part of DOE comes when you're putting it into practice, and you hit a point where you don't know what to do next. A compilation of others' experiences to fall back on always comes in handy... ??? ???

Read his full post?

?? An ode to the TEMPEST?

Our automation specialist Daniel Yip's?latest review paid tribute to the TEMPEST? from FORMULATRIX ?. From input and output plate stackers to a lightning-fast plate shuttle, he's got high hopes for how it can help scientists automate high-throughput experiments.?

Watch it in action and read his report?


?? Content we're loving

Iatrogenic Alzheimer’s disease in recipients of cadaveric pituitary-derived growth hormone

Why we loved it: Love is the wrong word—it was concerning, and important enough to stop us in our tracks mid-scroll.

It's possible that Alzheimer’s disease (AD) could've been transmitted through a now-banned growth hormone, which was used to treat UK children from the 1960s to 1980s.

It contained measurable amounts of amyloid beta (Aβ), a sticky protein fragment, and the accumulation of Aβ within the brain is a key pathological characteristic of AD.

This study found that out of the 8 now-adults, 5 of them met the criteria for an Alzheimer’s diagnosis, while out of the remaining 2, one had cognitive impairment, and the other had Aβ build-up in the cerebrospinal fluid.?


Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting?

Why we loved it: Success in therapies to treat deafness has been limited to cochlear implants… until now.

This clinical trial found that cochlear injections of the OTOF gene, carried within a viral vector, resulted in the partial restoration of hearing in an 11-year-old child.

The OTOF gene encodes the otoferlin protein, which, in its functional state, is involved in neurotransmitter release within the inner hair cells of the cochlea.


Pupil responses to colorfulness are selectively reduced in healthy older adults

Why we loved it: Who knew that our perception of colors changes as we age?

By using pupillometry to measure pupil constriction, researchers found that healthy older adults are less sensitive to color chroma (or colorfulness) than younger adults, but not colour lightness.

This difference in chroma perception was particularly apparent in the Green-Magenta axis.


About Synthace

Get faster, smarter insights from your R&D experiments. Designed by and for biologists, Synthace lets you design powerful experiments, run them in your lab, then automatically build structured data. No code necessary. Learn more.

Get the latest from our lab team

Scientists Luci and Fatima keep you posted on DOE, lab automation, plus all things current and future-facing in life sciences R&D.

No frills. Just the important stuff.

Subscribe for email updates here.

要查看或添加评论,请登录

Synthace的更多文章

社区洞察

其他会员也浏览了